09:52 AM EST - Theralase Technologies Inc. : Announced today that its latest research demonstrates that its lead Photo Dynamic Compound, TLD-1433, in addition to being indicated for the treatment of Non-Muscle Invasive Bladder Cancer, may also be effective for the treatment of Muscle Invasive Bladder Cancer. Theralase Technologies Inc.
shares V.TLT are trading up $0.025 at $0.31.
